Tower Research Capital (TRC)’s Hepion Pharmaceuticals HEPA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-110
| Closed | -$47 | – | 5384 |
|
|
2025
Q1 | $47 | Sell |
110
-6
| -5% | -$58 | ﹤0.01% | 5078 |
|
|
2024
Q4 | $2.74K | Sell |
116
-21
| -15% | -$656 | ﹤0.01% | 4783 |
|
|
2024
Q3 | $4.59K | Buy |
137
+21
| +18% | +$831 | ﹤0.01% | 4488 |
|
|
2024
Q2 | $5.92K | Buy |
116
+78
| +205% | +$5.75K | ﹤0.01% | 4640 |
|
|
2024
Q1 | $4.73K | Buy |
38
+6
| +19% | +$690 | ﹤0.01% | 4640 |
|
|
2023
Q4 | $5.24K | Sell |
32
-12
| -27% | -$2.27K | ﹤0.01% | 4863 |
|
|
2023
Q3 | $11.1K | Buy |
44
+39
| +780% | +$14.6K | ﹤0.01% | 4041 |
|
|
2023
Q2 | $2.79K | Sell |
5
-6
| -55% | -$3.68K | ﹤0.01% | 5151 |
|
|
2023
Q1 | $8K | Sell |
11
-21
| -66% | -$15.5K | ﹤0.01% | 4633 |
|
|
2022
Q4 | $10K | Buy |
32
+12
| +60% | +$5.07K | ﹤0.01% | 4006 |
|
|
2022
Q3 | $10K | Buy |
20
+8
| +67% | +$4.88K | ﹤0.01% | 4535 |
|
|
2022
Q2 | $7K | Buy |
12
+10
| +500% | +$8.33K | ﹤0.01% | 4792 |
|
|
2022
Q1 | $2K | Buy |
+2
| New | +$2.21K | ﹤0.01% | 5556 |
|
|
2021
Q3 | – | Sell |
-3
| Closed | -$7K | – | 5921 |
|
|
2021
Q2 | $7K | Sell |
3
-22
| -88% | -$40.3K | ﹤0.01% | 4556 |
|
|
2021
Q1 | $46K | Buy |
+25
| New | +$54.8K | ﹤0.01% | 3194 |
|
|
2020
Q4 | – | Sell |
-5
| Closed | -$14K | – | 5245 |
|
|
2020
Q3 | $14K | Buy |
+5
| New | +$17.9K | ﹤0.01% | 3963 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 4644 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 4458 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 3446 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 2556 |
|
|
2015
Q2 | – | Hold |
0
| – | -$3K | – | 4638 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 3563 |
|
Other funds holding HEPA
Tower Research Capital (TRC)'s HEPA Position: Q2 2025 in Review
Tower Research Capital (TRC) sold out of Hepion Pharmaceuticals (HEPA) in Q2 2025, closing a stake of 110 shares — an estimated $47 sold.
Tower Research Capital (TRC) first reported a position in HEPA in Q3 2020 and held it in 16 quarters. The position peaked at $46K in Q1 2021. 4 funds tracked by Wall St. Rank hold HEPA as of Q2 2025.
- Tower Research Capital (TRC) reported no remaining Hepion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 110 Hepion Pharmaceuticals shares in Q2 2025, an estimated $47.
- Tower Research Capital (TRC) first reported a position in Hepion Pharmaceuticals in Q3 2020 and held it in 16 quarters.
- Tower Research Capital (TRC)'s Hepion Pharmaceuticals position peaked at $46K in Q1 2021.
- 4 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2025, filed 15 Aug 2025.